Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may end painful bone marrow biopsies for myeloma patients

NCT ID NCT07691034

Knowledge-focused Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether a blood test using mass spectrometry can detect minimal residual disease (tiny amounts of cancer left after treatment) in multiple myeloma patients. Currently, doctors must take bone marrow samples, which is painful and inconvenient. The blood test would be easier and could be done more often. Researchers will compare the blood test results with standard bone marrow tests and PET scans in 40 patients who are in deep remission.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could replace painful bone marrow biopsies with a simple blood test for monitoring multiple myeloma remission.
What could go wrong
This is a small, early-stage study. The blood test may not be sensitive enough to catch all residual cancer cells, and results need validation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Multiple Myeloma patients in stringent complete remission for for than six months

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Multiple Myeloma patients in sCR for more than 6 months * Diagnostic bone marrow and blood/serum material biobanked at diagnosis according to established diagnostic biobank * Informed, written consent Exclusion Criteria: * Phychiatric disease or other condition where the subject may be non-compliant * Not able to read and understand Danish language * Bleeding disorder, thrombocyte counts below 20 mia/L

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Minimal residual disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Minimal residual disease Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.